Bone Metabolism in Cholestatic Children Before and After Living-Related Liver Transplantation-a Long-Term Prospective Study

Journal of Clinical Densitometry

Volumn 15, Issue 2, 2012, Pages 233-240

  Kryskiewicz, Edyta ^a   Pawlowska, Joanna ^a   Pludowski, Pawel ^a   Ismail, Hor ^a   Karczmarewicz, Elzbieta ^a   Teisseyre, Mikolaj ^a   Skorupa, Ewa ^a   Ryzko, Jozef ^a   Kalicinski, Piotr ^a   Socha, Jerzy ^a   Lorenc, Roman S ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Bone metabolism; Bone turnover markers; DXA; Liver transplantation; Skeletal status

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISONE; PROCOLLAGEN N PROTEINASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TELOPEPTIDE;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CHILD; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER FUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; CHOLESTASIS; FEMALE; HUMANS; INFANT; LIVER TRANSPLANTATION; MALE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84860472587     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.09.007     Document Type: Article

References (32)

1. Chardot C. Biliary atresia. Orphanet J Rare Dis 2006, 1:28-36.
2. Pereira T.N., Walsh M.J., Lewindon P.J., Ramm G.A. Paediatric cholestatic liver disease: diagnosis, assessment of disease progression and mechanisms of fibrogenesis. World J Gastrointest Pathophysiol 2010, 1:69-84.
3. Hartley J.L., Davenport M., Kelly D.A. Biliary atresia. Lancet 2009, 374:1704-1713.
4. Shneider B.L., Mazariegos G.V. Biliary atresia: a transplant perspective. Liver Transpl 2007, 13:1482-1495.
5. Sokal E.M., Goldstein D., Ciocca M., et al. End-stage liver disease and liver transplant: current situation and key issues. J Pediatr Gastroenterol Nutr 2008, 47:239-246.
6. Gasser W.R. Cholestasis and metabolic bone disease-a clinical review. Wien Med Wochenschr 2008, 158/19-20:553-557.
7. Klein G.L., Soriano H., Shulman R.J., et al. Hepatic osteodystrophy in chronic cholestasis: evidence for a multifactorial etiology. Pediatr Transplant 2002, 6:136-140.
8. Helenius I., Remes V., Salminen S., et al. Incidence and predictors of fractures in children after solid organ transplantation: a 5-year prospective, population-based study. J Bone Miner Res 2006, 21:380-387.
9. D'Antiga L., Moniz C., Buxton-Thomas M., et al. Bone mineral density and height gain in children with chronic cholestatic liver disease undergoing transplantation. Transplantation 2002, 73:1788-1793.
10. Okajima H., Shigeno C., Inomata Y., et al. Long-term effects of liver transplantation on bone mineral density in children with end-stage liver disease: a 2-year prospective study. Liver Transpl 2003, 9:360-364.
11. Hill S.A., Kelly D.A., John P.R. Bone fractures in children undergoing orthotopic liver transplantation. Pediatr Radiol 1995, 25(Suppl 1):112-117.
12. Valta H., Jalanko H., Holmberg C., et al. Impaired bone health in adolescents after liver transplantation. Am J Transplant 2008, 8:150-157.
13. Guthery S.L., Pohl J.F., Bucuvalas J.C., et al. Bone mineral density in long-term survivors following pediatric liver transplantation. Liver Transpl 2003, 9:365-370.
14. Khan K., Raatz S., Sharp H. Bone mineral density in adults transplanted in childhood for liver disease. Transplant Proc 2006, 38:1453-1455.
15. Ulivieri F.M., Lisciandrano D., Gridelli B., et al. Bone mass and body composition in children with chronic cholestasis before and after liver transplantation. Transplant Proc 1999, 31:2131-2134.
16. de Albuquerque Taveira A.T., Fernandes M.I., Galvao L.C., et al. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol (Oxf) 2007, 66:518-523.
17. D'Antiga L., Ballan D., Luisetto G., et al. Long-term outcome of bone mineral density in children who underwent a successful liver transplantation. Transplantation 2004, 78:899-903.
18. Pludowski P., Matusik H., Olszaniecka M., et al. Reference values for the indicators of skeletal and muscular status of healthy Polish children. J Clin Densitom 2005, 8:164-177.
19. Palczewska I., Niedźwiecka Z. Somatic development indices in children and youth of Warsaw. Med Wieku Rozwoj 2001, 2(Suppl 1):121-132.
20. Leonard M.B., Bachrach L.K. Assessment of bone mineralization following renal transplantation in children: limitations of DXA and the confounding effects of delayed growth and development. Am J Transplant 2001, 1:193-196.
21. Argao E.A., Balistreri W.F., Hollis B.W., et al. Effect of orthotopic liver transplantation on bone mineral content and serum vitamin D metabolites in infants and children with chronic cholestasis. Hepatology 1994, 20:598-603.
22. Buzi F., Bontempelli A.M., Alberti D., et al. Growth, insulin-like growth factor I (IGF-I), and IGF-binding proteins 1 and 3 in children with severe liver disease before and after liver transplantation: a longitudinal and cross-sectional study. Pediatr Res 1998, 43:478-483.
23. Holt R.I., Jones J.S., Stone N.M., et al. Sequential changes in insulin-like growth factor I (IGF-I) and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996, 81:160-168.
24. Kream B.E., Graves L., Lukert B.P. Clinical and basic aspects of glucocorticoid action in bone. Principles of Bone Biology 2008, 955-981. Academic Press, San Diego, CA. 3rd ed. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
25. Lane N.E., Yao W. New insights into the biology of glucocorticoid-induced osteoporosis. IBMS BoneKEy 2011, 8:229-236.
26. Libanati C., Rajaram S., Baylink D.J., Mohan S. In a longitudinal prospective study, glucocorticoid (GC) therapy causes a marked reduction in bone formation markers and stimulatory insulin-like growth factor (IGF) system components. J Bone Miner Res 1996, 11(Suppl 1):150.
27. Tamler R., Epstein S. Nonsteroid immune modulators and bone disease. Ann N Y Acad Sci 2006, 1068:284-296.
28. Blake G.M., Fogelman I. Methods and clinical issues in bone densitometry. Principles of Bone Biology 2008, 1882-1894. Academic Press, San Diego, CA. 3rd ed. J.P. Bilezikian, L.G. Raisz, T.J. Martin (Eds.).
29. Schönau E., Rauch F., Blum W.F. Growth prediction models: setting the scene. Prediction of Growth Response to GH Treatment. A Reference Guide 2001, 3-21. TMG Healthcare Communications Ltd, Abingdon, UK. E. Schönau, F. Rauch, W.F. Blum (Eds.).
30. Alvarez L., Guañabens N., Peris P., et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001, 29:447-452.
31. Seibel M.J. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000, 6(Suppl):S18-S29.
32. Vesper H.W. Analytical and preanalytical issues in measurement of biochemical bone markers. Lab Med 2005, 36:424-429.